Professor Christopher E Shaw MBChB, MD, FRACP, FRCP
Professor of Neurology and Neurogenetics
Head of Department of Clinical Neurosciences
Director of the King's Clinical Neurosciences Institute
 | |
| contact this person | |
| tel | +44 (0)207 848 5183 |
| fax | +44 (0)207 848 0988 |
| address | Institute of Psychiatry |
| location | 105 1 - 2 Windsor Walk |
| departments | Clinical Neuroscience MRC Centre for Neurodegeneration Research Neurodegeneration and Brain Injury |
biography
Christopher Shaw is Professor of Neurology and Neurogenetics at the Institute of Psychiatry, King’s College London. He is also an Honorary Consultant Neurologist at King’s College Hospital and Neurogeneticist at Guy’s and St Thomas’ Hospitals. His early training in General Medicine and Neurology was conducted in New Zealand. He came to Cambridge in 1992 on a Wellcome Trust Fellowship to study Neurobiology. In 1995 he moved to the Institute of Psychiatry. His major area of clinical and research interest is in the genetic and molecular basis of motor neurone disease (MND, also known as Amyotrophic Lateral Sclerosis or Lou Gherig’s disease). He runs a clinic for patients with MND/ALS at King’s College Hospital and for other inherited neurological disorders at Guy’s Hospital.
activities and interests
Head of Genetics Laboratory
His research team are currently:
1. Hunting new MND/ALS disease causing gene mutations using genetic linkage analysis in families with inherited forms of MND/ALS.
Recent findings include the identification of mutations in TARDBP
(Sreedharan et al Science epub Feb 2008).
Identification of the FTD/ALS2 locus
(Vance, et al. Brain 2006 129:868-876)
Identification of the ALS6 locus
(Ruddy et al. American Journal of Human Genetics 2003; 73 360-369.)
2. Identifying genetic variants that predispose certain people to get MND/ALS in the absence of a family history, so called sporadic disease.
Association study of SOD1 locus in non-SOD1 mutant sporadic ALS
1. (WJ Broom, et al. Neurology 2004, 63:2419-22.)
Mutation screening of CHMP2B in sporadic ALS
Blair IP, J Neurol Neurosurg Psychiatry. 2008 Feb 12; [Epub]
3. Co-ordinating a UK Biobank of MND patient DNA samples and lymphoblast cell lines
4. Identifying proteins that accumulate and contribute to the death of motor neurones in animal models and patient samples. Searching for diagnostic and disease activity biomarkers in spinal fluid and blood to improve the speed and accuracy of diagnosis and provide an objective measure of drug efficacy
5. Developing a high-throughput screen in cellular models of MND using yeast cells and embryonic stem cells.
His research team are currently:
1. Hunting new MND/ALS disease causing gene mutations using genetic linkage analysis in families with inherited forms of MND/ALS.
Recent findings include the identification of mutations in TARDBP
(Sreedharan et al Science epub Feb 2008).
Abstract: http://www.sciencemag.org/cgi/content/abstract/1154584?ijkey=SLsmF/oDC3.3U&keytype=ref&siteid=sci
Reprint: http://www.sciencemag.org/cgi/rapidpdf/1154584?ijkey=SLsmF/oDC3.3U&keytype=ref&siteid=sci
Identification of the FTD/ALS2 locus
(Vance, et al. Brain 2006 129:868-876)
Identification of the ALS6 locus
(Ruddy et al. American Journal of Human Genetics 2003; 73 360-369.)
2. Identifying genetic variants that predispose certain people to get MND/ALS in the absence of a family history, so called sporadic disease.
Association study of SOD1 locus in non-SOD1 mutant sporadic ALS
1. (WJ Broom, et al. Neurology 2004, 63:2419-22.)
Mutation screening of CHMP2B in sporadic ALS
Blair IP, J Neurol Neurosurg Psychiatry. 2008 Feb 12; [Epub]
3. Co-ordinating a UK Biobank of MND patient DNA samples and lymphoblast cell lines
4. Identifying proteins that accumulate and contribute to the death of motor neurones in animal models and patient samples. Searching for diagnostic and disease activity biomarkers in spinal fluid and blood to improve the speed and accuracy of diagnosis and provide an objective measure of drug efficacy
5. Developing a high-throughput screen in cellular models of MND using yeast cells and embryonic stem cells.
last updated: Monday, March 03, 2008